Aquestive Therapeutics, Inc. (AQST)

Market Cap	467.27M +69.7%
Revenue (ttm)	43.40M -26.3%
Net Income	-68.98M
EPS	-0.70
Shares Out	122.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,796,516
Open	3.870
Previous Close	3.880
Day's Range	3.760 - 3.985
52-Week Range	2.120 - 7.550
Beta	1.66
Analysts	Strong Buy
Price Target	8.83 (+130.55%)
Earnings Date	Mar 6, 2026

About AQST

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease; and Azstarys, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jul 25, 2018
• Employees: 142
• Stock Exchange: NASDAQ
• Ticker Symbol: AQST
• Website: https://www.aquestive.com

Financial Performance

In 2024, Aquestive Therapeutics's revenue was $57.56 million, an increase of 13.80% compared to the previous year's $50.58 million. Losses were -$44.14 million, 460.8% more than in 2023.

Analyst Summary

According to 6 analysts, the average rating for AQST stock is "Strong Buy." The 12-month stock price target is $8.83, which is an increase of 130.55% from the latest price.

Price Target

$8.83

(130.55% upside)

Analyst Consensus: Strong Buy